Aims and background. It is still unclear whether age is an independent prognostic factor in patients with stage I NSCLC.
Introduction
Lung cancer is the most common cause of cancer-related death in many countries, but the 5-year survival of patients with non-small cell lung cancer (NSCLC) has been slowly improving and is now 16% 1 . In patients with stage I NSCLC, 5-year survival is still disappointing at 58-73% 2 , and adjuvant chemotherapy seems even to be harmful by lung ad-juvant cisplatin evaluation meta-analysis 3 . The recent increase in incidence of stage I lung cancer, especially adenocarcinoma, has been suggested to be attributable to the effects of screening for lung cancer, increased awareness of lung cancer, and ethnic differences or environmental factors, but its cause remains largely unclear.
In addition to the development of prognostic biomarkers, another issue in terms of identifying biologic differences or choosing the subgroup needing adjuvant treatment is clinical factors affecting prognosis at this stage of disease. Compared with older patients with lung cancer, younger patients may be less likely to be exposed to cigarette smoke or have significant comorbidities and more likely to have different tumor biology [4] [5] [6] . Therefore, we thought age was a potentially important prognostic factor. However, studies investigating whether age has a prognostic value have shown inconsistent results 7, 8 . In numerous previous studies, the prognostic values of gender, smoking, comorbidity, histology, tumor size and lymphatic or blood vessel invasion have been identified in stage I NSCLC patients [5] [6] [7] [9] [10] [11] [12] [13] [14] [15] [16] , but in most series the prognostic relevance of all of these clinical variables was not verified. Moreover, some studies consisted of small numbers of patients or varieties of tumor histology, stage, or treatment given.
The present study was therefore limited to patients with pathologically staged T1-2, N0, M0 adenocarcinoma to reduce confounding effects on survival analysis possibly attributable to differences in stage or histology, and we evaluated the prognostic relevance of these clinical variables.
Methods

Patients
Of patients retrospectively enrolled in a study on the development of biomarkers for stage I NSCLC using tissue microarrays, those with adenocarcinoma of the lung were selected for inclusion in the study. Patients underwent complete surgical resection between January 1997 and December 2005 according to the recommendations of the American Joint Committee on Cancer, sixth edition 17 . After patients who received preoperative chemotherapy, radiation therapy or target agents or who had previous lung cancer were excluded, 569 patients were included in the study. Information regarding smoking habits, Charlson comorbidity index score (CCIS), type of surgery, tumor size, type of histology (adenocarcinoma or pure bronchioloalveolar carcinoma), lymphatic vessel invasion, blood vessel invasion in the pathologic specimen, and adjuvant treatment was collected using uniform data sheets from 11 university hospitals in Korea. The study was approved by the Institutional Review Boards of each hospital. Informed consent of patients was waived.
Survival measurements
The end point of the study was overall survival estimated from the date of surgery. Dates of death were obtained mainly from reviewing medical records. To increase the quality of information on survival status in patients lost to follow-up, information about survival was obtained by contacting the patients or their relatives by phone or mail, or from the Ministry of Public Administration and Security, South Korea. Of the 569 patients, 178 (31.8%) were dead and 391 alive.
Statistical analysis
The patients were divided into four groups according to quartiles of age. The cutoff values of the 25 th , 50 th and 75 th percentile of age were 55, 62 and 68 years old, respectively. The c 2 test and Fisher's exact test for heterogeneity were used to compare the distributions of the clinical variables between the groups. The effects of each clinical variable as well as the age groups on overall survival rates were estimated using the Kaplan-Meier method. The difference in overall survival curves among subgroups of each clinical variable was tested using the logrank test. The hazard ratio (HR), adjusted for potential confounders, and the 95% confidence interval (CI) were estimated using the Cox proportional hazards model. Statistical significance was assumed at the two-sided 0.05 level. All statistical analyses were performed using the SAS software package (v. 9.1.3, SAS institute, Cary, NC, USA). Table 1 provides the demographic and clinical characteristics of the patients by age group. Median age was 62.0 years (range, 21-82). The patients consisted of 312 men (22.4% never smokers, 77.6% smokers) and 257 women (90.2% never smokers, 9.8% smokers). Pure bronchioloalveolar carcinoma was more commonly seen in women than in men (33.3% vs 21.2%, P = 0.001) (data not shown). The distributions of gender, smoking habit, CCIS, histology, blood vessel invasion and adjuvant chemotherapy were shown to be significantly different among the four age groups (P <0.05). The highest quartile of age (eldest group) showed a tendency of being men, ever smoker, higher CCIS, adenocarcinoma, and low probability of having blood vessel invasion or receiving adjuvant chemotherapy.
Results
Characteristics of patients
Comparison of survival rates for clinical variables
The 5-year survival of the 569 patients was 73%. Median survival time of the patients had not been reached at this writing (data not shown). Overall survival rates were significantly different among the four age groups (logrank P <0.001, Figure 1 ). ter survival rate than adenocarcinoma, but the difference was not significant (logrank P = 0.056).
Adjusted hazards ratios being affected by risk factors
The risk of death in the group of the highest quartile of age (≥68 years old) was significantly increased compared to that of the lowest quartile of age (<55 years old) after adjustment for gender, CCIS, smoking habit, type of histology, tumor size, lymphatic or blood vessel invasion and adjuvant chemotherapy (adjusted HR = 2.735; 95% CI, 1.623-4.608; P <0.001) ( Table 2 ). In addition, the risk for death was significantly higher for the largest (>5 cm) tumor (adjusted HR = 2.813; 95% CI, 1.531-5.168; P = 0.001). Other clinical variables including gender, smoking habit, CCIS, type of histology lymphatic or blood vessel invasion and adjuvant chemotherapy were not associated with risk of death after the adjustment.
Discussion
In the study, we demonstrated that age has an important prognostic value in patients with stage I adenocarcinoma regardless of other clinical variables: gender, smoking habit, comorbidity, type of histology, tumor size and lymphatic or blood vessel invasion. Therefore, In proportion as the quartiles increase from low to high, overall survival showed a tendency of being shorter. Overall survival curves among the subgroups of gender, smoking habit, CCIS, tumor size, lymphatic or blood vessel invasion were significantly different (Figure 2) . Pure bronchioloalveolar carcinoma showed bet- age should be considered in classifying the patients into groups of higher or lower risk of death as well as in designing clinical trials.
In the study, the results of the Cox proportional hazards model indicated that risk of death showed tendencies of increasing with age (quartile) as well as with tumor size, in line with the T descriptor of the currently recommended staging system proposed by the International Association for the Study of Lung Cancer 2 .
Effect of age on survival of stage I NSCLC patients has been reported with inconsistent results. In a report by Bryant et al. 7 , younger age (<45 years old) was associated with a poor survival compared with older patients. However, their population consisted of groups heterogenous in stage and histology, and the effect of age on overall survival disappeared in multiple analysis. Moreover, there has been no criterion of defining younger and older in terms of biologic age as well as considering carcinogenesis of lung cancer. Therefore, it is not reasonable that age is considered as a dichotomous variable with a specific cutoff value for age instead of a continuous one or a categorical variable by classifying into three or four classes as done in the present study. Shoji et al. 9 reported that blood vessel invasion was a significant prognostic factor whereas age did not affect survival of the patients with stage IA NSCLC.
In contrast, Fujisawa et al. 18 demonstrated that age and smoking habit were independent prognostic factors after adjustment for gender, type of histology, tumor differentiation and tumor size in patients with stage I NSCLC. Using the Surveillance, Epidemiology, and End Results (SEER) data base, Subramanian et al. 8 recently conducted multiple analyses on survival of NSCLC patients and showed that the risk of death increases with age, but they did not evaluate the effect of important confounders like smoking habit and comorbidity because of limitations of the SEER database.
As expected, the highest quartile of age (eldest group) showed a tendency of being men, ever smoker, higher CCIS, and low probability of taking adjuvant chemotherapy in the present study. These clinical variables may have potential interactions with age as confounders. Except for adjuvant chemotherapy whose benefit in stage I NSCLC patients is still a controversial issue, these clinical characteristics were deemed to have an effect on survival of the patients. All of these clinical variables should be taken into account in the development of a more robust prognostic model. Therefore, we evaluated the prognostic relevance of these clinical variables, which was taken into account in multiple Cox proportional hazards regression analysis.
In addition to differences in clinical characteristics as age increases, Mostertz et al. 4 recently noted different patterns of gene expression between younger and older NSCLC patients, where age was a determinant of overall survival of the patients. Therefore, we believe that differences in these clinical and biologic phenotypes between younger and older patients are plausible reasons for a prognostic significance of age.
The study has several limitations because it was conducted by retrospective analysis of the patients treated at 11 university hospitals, and bias could be present. Furthermore, overall survival, but not lung cancer-specific survival, was evaluated in the study. Overall survival could be affected by and overestimated because of the presence of comorbidities, particularly smoking-related disease, in patients with lung cancer. Nevertheless, we believed this possibility can be decreased by limiting the study to the patients with adenocarcinoma and investigating CCIS and smoking habit and taking them into account in multiple Cox proportional hazards regression analysis of the study. 
